Department Of Medicine, Mount Sinai St.Lukes-Roosevelt, Icahn School Of Medicine At Mount Sinai, New York, NY, USA.
Department Of Immunology, Mayo Clinic, Rochester, MN, USA.
Expert Opin Investig Drugs. 2021 Sep;30(9):947-963. doi: 10.1080/13543784.2021.1964471. Epub 2021 Aug 13.
Despite tremendous advances, the shortcomings of current therapies for coronary disease are evidenced by the fact that it remains the leading cause of death in many parts of the world. There is hence a drive to develop novel therapies to tackle this disease. Therapeutic approaches to coronary angiogenesis have long been an area of interest in lieu of its incredible, albeit unrealized potential.
This paper offers an overview of mechanisms of native angiogenesis and a description of angiogenic growth factors. It progresses to outline the advances in gene and stem cell therapy and provides a brief description of other investigational approaches to promote angiogenesis. Finally, the hurdles and limitations unique to this particular area of study are discussed.
An effective, sustained, and safe therapeutic option for angiogenesis truly could be the paradigm shift for cardiovascular medicine. Unfortunately, clinically meaningful therapeutic options remain elusive because promising animal studies have not been replicated in human trials. The sheer complexity of this process means that numerous major hurdles remain before therapeutic angiogenesis truly makes its way from the bench to the bedside.
尽管取得了巨大的进展，但当前治疗冠心病的方法仍存在不足，这在一定程度上表明，冠心病仍是世界上许多地区的主要死亡原因。因此，人们致力于开发新的疗法来治疗这种疾病。治疗性冠状动脉生成一直是人们感兴趣的领域，因为它具有巨大的、但尚未实现的潜力。
本文概述了内源性血管生成的机制，并描述了血管生成生长因子。接着概述了基因和干细胞治疗的进展，并简要描述了促进血管生成的其他研究方法。最后，讨论了该特定研究领域特有的障碍和局限性。
对于血管生成来说，真正有效的、持续的、安全的治疗选择可能是心血管医学的范式转变。不幸的是，临床上有意义的治疗选择仍然难以捉摸，因为有希望的动物研究在人体试验中没有得到复制。这个过程非常复杂，这意味着在治疗性血管生成真正从实验室走向临床之前，还有许多重大的障碍需要克服。
